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Abstract. Genetic heterogeneity is recognized as a major
contributing factor of glioblastoma resistance to clinical treatment modalities and consequently low overall survival rates.
This genetic diversity results in variations in protein expression, both intratumorally and between individual glioblastoma
patients. In this regard, the spectraplakin protein, microtubule
actin cross-linking factor 1 (MACF1), was examined in glioblastoma. An expression analysis of MACF1 in various types
of brain tumor tissue revealed that MACF1 was predominately
present in grade III-IV astroctyomas and grade IV glioblastoma, but not in normal brain tissue, normal human astrocytes
and lower grade brain tumors. Subsequent genetic inhibition
experiments showed that suppression of MACF1 selectively
inhibited glioblastoma cell proliferation and migration in cell
lines established from patient derived xenograft mouse models
and immortalized glioblastoma cell lines that were associated
with downregulation of the Wnt-signaling mediators, Axin1
and β-catenin. Additionally, concomitant MACF1 silencing
with the chemotherapeutic agent temozolomide (TMZ) used
for the clinical treatment of glioblastomas cooperatively
reduced the proliferative capacity of glioblastoma cells. In
conclusion, the present study represents the first investigation
on the functional role of MACF1 in tumor cell biology, as well
as demonstrates its potential as a unique biomarker that can be
targeted synergistically with TMZ as part of a combinatorial
therapeutic approach for the treatment of genetically multifarious glioblastomas.
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Introduction
Glioblastomas have an age adjusted incidence of 3 per 100,000
persons per year in the United States and comprise approximately 45% of all gliomas with a relative survival rate of 5%,
5-years post-diagnosis (1), which can be attributed in part to
high rates of tumor recurrence. A major contributor to the
low survival rates of patients with these cancers is the incredibly complex glioblastoma genome, which has a vast number
of uncharacterized expressed genetic abnormalities that
contribute to intra- and intertumor variation that negatively
impact therapeutic response and patient outcomes (2). The
poor prognosis of brain tumor patients, particularly those with
glioblastoma, can be attributed in part to the limited number
of aberrantly expressed factors used clinically as diagnostic
and prognostic indicators. These have included genetic mutations, deletions, amplifications, and epigenetic changes in
isocitrate dehydrogenase (IDH), EGFR and O6-methylguanine
DNA methyltransferase (MGMT) (3-8). In the present study,
we investigated microtubule actin cross-linking factor 1
(MACF1), which functions to crosslink microtubules and
actin filaments, for its role in tumor cell biology and as a novel
target in glioblastoma. Although to date MACF1 has received
little consideration in tumor cell biology and as a target in
human cancers, its function as a cytoskeleton integrator has
been shown to be involved in organization of the cytoskeleton (9), tissue repair (10) and vertebrate development (11).
These studies provided correlative evidence that MACF1 is
involved in processes such as metastatic invasion in which
cytoskeleton organization is a key element that contributes
to tumor progression in various human cancers, as well as
cellular and physiological processes such as tissue repair
when dysregulated in normal tissue can lead to tumorigenesis.
Additionally, studies by Sjöblom et al (12) identified MACF1
as a candidate breast cancer gene in a mutational analysis
study, while Misquitta-Ali et al (13) detected alternatively
spliced exons in MACF1 transcripts from lung cancer patients
providing further evidence, albeit circumstantial, that MACF1
plays a role in human cancer. In the present study, we demonstrated that genetic inhibition of MACF1, which we found to
be expressed at high levels in glioblastoma relative to normal
brain tissue, had anti-tumorigenic effects on glioblastoma
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cell behavior and a synergistic effect with temozolomide, an
alkylating agent used clinically to treat this disease. To the
best of our knowledge, this is the first investigation to evaluate
the functional role of MACF1 in human cancers and as a target
that enhances the efficacy of therapeutic treatment modalities.
Materials and methods
Cells culture conditions and reagents. U251 human glioblastoma cells were purchased from Sigma-Aldrich (St. Louis,
MO, USA) and the U87 and A172 human glioblastoma cells
were from the American Type Culture Collection (ATCC;
Manassas, VA, USA). Normal human astrocytes were obtained
from Sciencell Research Laboratories (Carlsbad, CA, USA).
All cell lines were maintained in Dulbecco's modified Eagle's
medium-DMEM (Invitrogen, Carlsbad, CA, USA) containing
10% fetal bovine serum (FBS; Invitrogen), 2 mM L-glutamine
(Invitrogen), 100 nM MEM non-essential amino acids
(Invitrogen) and penicillin-streptomycin (Invitrogen) at 37˚C
and 5% CO2. Accell SMARTpool siRNAs targeting MACF1
were purchased from GE Dharmacon (Chicago, IL, USA).
Temozolomide was purchased from Sigma-Aldrich. GBM76
patient derived xenograft cells were established at the Mayo
Clinic (Rochester, MN, USA) (14), while primary xenograft
lines T4105 and T4302 were provided by Jeremy Rich from
the Cleveland Clinic (Cleveland, OH, USA). Patient derived
xenograft cell lines (GBM76, T4105 and T4302) were serially
passaged as subcutaneous tumors in immunocompromised
mice and maintained as ex vivo cultures in neurobasal medium
supplemented with B27 serum substitute, 20 ng/ml EGF and
20 ng/ml bFGF (Life Technologies, Carlsbad, CA, USA).
Immunohistochemistry. Brain tumor tissue arrays were
purchased from US Biomax, Inc., (Rockville, MD, USA)
to evaluate MACF1 expression. Each slide contained the
following number and array of brain tumor tissue sections
provided by the supplier: 10 grade (I-II) astrocytomas, 10
grade (III-IV) astrocytomas, 33 grade (IV) glioblastomas,
3 oligoastrocytomas, 6 grade (I-II) oligodendrogliomas,
3 medulloblastomas, 3 anaplastic oligodendrogliomas, 4
ependymomas and cancer adjacent normal tissue from 5
brains. Paraffin-embedded tissue sections were dewaxed in
xylene for 5 min, rehydrated in 100% ethanol, 95% ethanol
and water. Next tissue was fixed with 100% methanol at
-20˚C for 15 min and washed three times with phosphatebuffered saline (PBS). Detection of MACF1 was conducted
using the ImmunoCruz rabbit ABC staining system (Santa
Cruz Biotechnology, Dallas, TX, USA). Tissue sections were
blocked for 1 h in 1.5% normal horse serum in PBS at room
temperature, permeabilized with 0.05% triton-x in PBS for
10 min, incubated overnight at 4˚C with a polyclonal MACF1
antibody (Santa Cruz Biotechnology) and rinsed three times
with PBS. Subsequently, sections were incubated with a
biotinylated secondary antibody for 3 h at room temperature
and washed in PBS three times 5 min each. Sections were
then incubated with an avidin-biotinylated HRP complex
for 30 min, rinsed again three times with PBS and MACF1
protein visualized as diaminobenzidine (DAB) positive
cells in tissue sections with a peroxidase substrate solution
containing substrate buffer, DAB and peroxidase substrate
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according to the manufacturer's instructions. Images were
then taken with a Leica DM4000 microscope and QImaging
system (Leica Microsystems, Inc., Buffalo Grove, IL, USA).
MACF1 silencing. For silencing experiments 3.5x104 U251,
A172, or patient derived xenograft cells were plated in 6-well
plates, grown for two days to 70% confluency, and treated with
1 µM non-targeting control siRNAs, 1 µM siRNAs targeting
MACF1 (GE Dharmacon), or shRNAs targeting MACF1
from the MISSION shRNA library (TRCN0000294117 and
TRCN0000294123; Sigma-Aldrich) and allowed to incubate
for 6 days in Accell media for siRNAs or neurobasal medium
for shRNAs. MACF1 expression was subsequently examined
in control and MACF1 silenced cells using immunoblotting
procedures.
Cell proliferation assay. To assess the effects of silencing
MACF1 on cell proliferation and viability, cells were treated
with 1 µM of non-targeting control siRNAs or siRNAs
targeting MACF1 (GE Dharmacon) and allowed to incubate
for 6 days in 6-well plates as described above. At the end of
the 6-day incubation period 1.5x104 cells treated with control
or siRNAs targeting MACF1 were replated in 12-well plates
and allowed to incubate in the absence of siRNAs for 2, 4,
and 6 days in DMEM media (Invitrogen) containing 10% FBS
(Invitrogen). At the end of each time-point cells were evaluated
using the crystal violet cell proliferation assay, one of three
standard assays that can be used to evaluate cytotoxicity and/or
cell viability that provide a measure of cell proliferation (15).
Tissue culture medium was removed and the cell monolayer
was fixed with 100% methanol for 5 min and stained with 0.5%
crystal violet in 25% methanol for 10 min. Cells were then
washed three times 5 min each with distilled water to remove
excess dye and allowed to dry overnight at room temperature.
The incorporated dye was then solubilized in 0.1 M sodium
citrate (Sigma-Aldrich) in 50% ethanol. Next, 100 µl of experimental samples were transferred to 96-well plates and optical
densities read at 540 nm using a xMark microplate absorbance
spectrophotometer (Bio-Rad Laboratories, Hercules, CA,
USA). For combinatorial experiments glioblastoma cells were
also first treated for 6 days with control non-targeting siRNAs
or siRNAs targeting MACF1, as previously described. Next
2.5x104 siRNA treated cells were replated in 12-well plates in
the absence of siRNAs. Controls and conditions for combinatorial experiments included: replated siRNA treated cells grown
for 72 h, replated siRNA treated cells exposed to TMZ or
DMSO 6 h after replating and allowed to incubate in TMZ or
DMSO for 72 h, and non-treated siRNA cells exposed to TMZ
or DMSO 6 h after plating and grown for 72 h in the presence
of TMZ or DMSO. DMSO is a solvent used to dissolve drugs
and was used as a vehicle control to discern the effects of TMZ
from the drug solvent. To evaluate the combinatorial effects
of silencing MACF1 and TMZ treatment on cell proliferation
and viability the cell proliferation assay, as described above,
was also used at the end of the 72-h incubation time-point.
Cell motility. Motility assays were conducted according to the
manufacturer's instructions (Cell Biolabs, Inc., San Diego, CA,
USA). MACF1 silencing was performed as described above.
Cell suspensions containing 0.5-1.0x106 cells/ml of siRNA
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Figure 1. MACF1 expression in brain tumors and normal brain tissue. MACF1 was robustly expressed in glioblastoma (A-C) but not detected in oligodendroglioma (D), medulloblastoma (E), or normal brain tissue (F). MACF1 protein is labeled as black diaminobenzidine (DAB) positive cells. Displayed is an
immunohistochemistry labeling experiment representative of three independent experiments that showed similar results (total magnification, x200).

control or siRNA targeted MACF1 treated cells were prepared
in serum-free media, while 500 µl of media containing 10%
fbs was added to the lower chamber of the migration plate.
A total of 300 µl of siRNA treated cell suspensions were then
added to the inside of each insert and were allowed to incubate
for 24 h at 37˚C and 5% CO2. Subsequently, non-migratory
cells were removed from plate inserts (per manufacturer's
instructions), migratory cells were stained with crystal violet
and the dye eluted as described above. Optical densities were
read at 595 nm using a xMark microplate absorbance spectrophotometer (Bio-Rad Laboratories) and statistical evaluation
of the data was performed as described below.
Western blotting. Cells treated for 6 days with control siRNAs
or siRNAs targeting MACF1 were rinsed with PBS and lysed
with CelLytic M Cell lysis reagent (Sigma-Aldrich). Protein
concentrations were subsequently determined using the
Bradford method. Proteins were separated by SDS-PAGE
in 4-15% polyacrylamide gels (Bio-Rad Laboratories), then
transferred to nitrocellulose membranes. For immunoblotting,
nitrocellulose membranes were incubated with MACF1 (Santa
Cruz Biotechnology), Axin1 (Cell Signaling Technology,
Danvers, MA, USA), phospho β -catenin (Cell Signaling
Technology) and GAPDH (Cell Signaling Technology)
antibodies recognizing target proteins overnight at 4˚C. The
membranes were then incubated with an HRP-conjugated
secondary antibody for 1 h at room temperature, analyzed
by enhanced chemiluminescence (ECL) detection system
(Thermo Fisher Scientific, Nashville, TN, USA) and visualized using a UVP BioSpectrum imaging system (UVP, LLC,
Upland, CA, USA). Densitometry analysis was performed
with the Image Studio Lite software (LI-COR Biosciences,
Lincoln, NE, USA).
Statistical analysis. Cell proliferation, migration, time-course
and combinatorial experiments were each performed at least

three times with duplicate or triplicate samples. Means were
determined by averaging duplicate or triplicate samples within
each independent experiment. Students t-tests and ANOVA
analysis were used to evaluate the significance between the
experimental conditions with a p-value of 0.05 and 0.01,
respectively.
Results
Differential expression of MACF1 in brain tumors. Identi
fication and expression profiling of tumor specific biomarkers
are essential for clinical diagnostic and prognostic purposes.
Using immunohistochemistry procedures we examined
MACF1 expression in low and high grade brain tumors. Our
data showed that MACF1 was expressed diffusely and at the
periphery in 40% of grade IV glioblastoma tissue sections as
compared to its absence in normal brain tissue (Fig. 1A-C).
In contrast to its expression in glioblastoma, MACF1 was
absent in lower grade brain tumors (oligodendroglioma and
medulloblastoma) and normal brain tissue (Fig. 1D-F), but
present in grade II-IV astrocytomas as compared to normal
brain tissue (Fig. 2). Complementing data observed in human
tissue, immunoblotting procedures of MACF1 in glioblastoma
cell lines also displayed significantly higher levels of MACF1
as compared to its expression in normal human astrocyte cells
(Fig. 2). Collectively, these data provide evidence that MACF1
is predominately expressed in high grade malignant brain
tumors and suggest that it is a potential biomarker and target
in these cancers.
Anti-tumorigenic effects of suppressing MACF1 in glioblastoma. MACF1 to date has received no consideration as a
target in cancer and associated cell behavior. Using siRNAs to
inhibit MACF1 function we assessed the effects of downregulating MACF1 expression on glioblastoma cell proliferation
and migration. Western blot experiments demonstrated the
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Figure 2. Western blot analysis of MACF1 expression in astrocytomas
and glioblastoma cell lines. Astrocytoma tissue taken from tumor patients
(top panel) and glioblastoma cell lines (bottom panel) displayed increased
MACF1 protein levels as compared to normal human astrocytes (NHA) and
normal brain tissue. Immunoblots are representative of at least four experiments that showed equivalent results. Actin was used as a loading control to
assess that lanes were loaded with the same amount of total proteins.
Figure 4. Downregulation of MACF1 impairs proliferation of patient derived
xenograft cell lines. Time-course analysis showed that inhibition of MACF1
with shRNAs decreased the proliferative capacity of patient derived glioblastoma cell lines established in xenograft mouse models.

Figure 3. Proliferative response of glioblastoma cells to MACF1 inhibition.
(A) Western blot analysis of U251 and A172 cells treated for six days with
MACF1 siRNAs nearly abolished MACF1 expression in U251 and A172 cells.
(B) Bar graphs show that reduction in MACF1 levels was accompanied with
a significant decrease in the proliferative capacity of U251 cells (*p<0.05 as
determined by the student's t-test; error bars, SE) but not A172 cells. Data
shown are representative of at least three independent experiments performed
in duplicate. Black bars, control siRNA treated cells; white bars, MACF1
siRNA treated cells.

efficacy of the siRNAs in silencing MACF1 in U251 and
A172 glioblastoma cells. Our data also revealed that silencing
MACF1 in U251 glioblastoma cells caused a 45 and 37%
decrease in cell viability 4 and 6 days post-treatment, respectively (Fig. 3). However, suppressing MACF1 expression did
not reduce A172 glioblastoma cell viability (Fig. 3). We further
evaluated the effects of inhibiting MACF1 in patient derived
xenograft cell lines (Fig. 4). Time course analysis displayed
that shRNAs targeting MACF1 significantly inhibited the

Figure 5. Effects of silencing MACF1 on glioblastoma cell migration.
Downregulation of MACF1 significantly impeded cell migration of U251
cells (top panel), but not A172 cells (bottom panel). Bar graphs displayed are
representative of three independent experiments performed in duplicate that
showed similar results. Black bars, control siRNA treated cells; white bars,
MACF1 siRNA treated cells (*p<0.05 as determined by the student's t-test;
error bars, SE).

growth of T4105 and T4302 xenograft cell lines, while SF295
and GBM76 cells were decreased to a much lesser extent
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Figure 6. Suppression of MACF1 reduced Axin1 and β-catenin expression.
Inhibition of MACF1 with siRNAs downregulated Axin1 and β -catenin
protein levels in U251 glioblastoma cells. (A) Western blot experiments and
(B) densitometric analysis. Data shown are representative of at least three
independent experiments that displayed comparative results.

Figure 8. Induction of MACF1 and Axin1 by TMZ. Densitometric analysis of
immunoblot showed that TMZ upregulated MACF1 and Axin1 protein levels
in U251 glioblastoma cells. Data shown are representative of at least three
independent experiments that displayed comparative results.

Figure 7. MACF1 repression with concurrent TMZ treatment. Glioblastoma
cells with silenced MACF1 treated with 100 µM TMZ led to a decrease
in glioblastoma cell proliferation compared to the treatment with vehicle
DMSO, control siRNAs, TMZ, or MACF1 siRNA alone as determined by
ANOVA analysis and Sidak's post hoc multiple comparisons test (*p<0.05,
**
p<0.01, ***p<0.001).

(Fig. 4). Consistent with the anti-proliferative effects of downregulating MACF1 protein levels in U251 cells, repression of
MACF1 also significantly reduced U251 cell migration but not
A172 cells (Fig. 5). Furthermore, because MACF1 has been
implicated as a modulatory signaling contributor of the Wnt
signaling pathway (16,17), whose dysregulation is well known
to be involved in tumor proliferation and migratory invasion in
a number of human cancers (18-20) including malignant brain
tumors (21-24) we evaluated the impact of silencing MACF1
on Wnt-signaling proteins. Our data showed that downregulation of MACF1 protein levels was accompanied by decreased
Axin1 and activated form of β-catenin protein levels (Fig. 6),
suggesting that reduction of these Wnt-signaling mediators
contribute to the anti-tumorigenic response of impairing
MACF1 in glioblastoma.
Synergistic effects of MACF1 inhibition and TMZ. Chemo
therapeutic agents used to treat glioblastoma have been
minimally effective in part as a consequence of expressed
genetic aberrations that contribute to intrinsic and acquired
tumor resistance (25). We subsequently performed combinatorial studies to test the effectiveness of downregulating MACF1

along with the effects of the alkylating agent, temozolomide
(TMZ) in glioblastoma cells. For combinatorial experiments, glioblastoma cells were treated with siRNAs targeting
MACF1 and 100 µM TMZ and compared to cells treated with
TMZ alone or cells treated with siRNAs targeting MACF1
alone. ANOVA analysis (p<0.01) of data from cell proliferation assays revealed that the combination of MACF1 and TMZ
treatment had the strongest effect on decreasing glioblastoma
cell viability when compared to other treatment conditions
and controls. Additionally, concurrent treatment of U251
glioblastoma cells with MACF1 targeting siRNAs and TMZ
exhibited a 1.5- and 2-fold cell viability decrease as compared
to cells treated with either MACF1 siRNAs or TMZ alone
(Fig. 7). A similar response was observed in A172 cells, which
displayed a 1.32- and 1.48-fold decrease in cell viability when
treated concurrently with TMZ and siRNAs targeting MACF1
as compared to treatment with either of these conditions
alone. We further examined by western blotting the effects of
TMZ on the expression levels of MACF1 and Axin1 in U251
cells treated for 3 h with 100 µM TMZ. These experiments
showed that TMZ increased the protein levels of MACF1
and the Wnt-cytoplasmic complex protein, Axin1 in U251
cells (Fig. 8), further supporting the combinatorial approach
and need to inhibit MACF1 in glioblastoma cells treated with
TMZ to achieve a synergistic effect.
Discussion
The scope of genetic abnormalities in the glioblastoma genome
was recently supported in a broad genome sequence study that
revealed 512 mutated genes in U87 glioblastoma cells, the most
commonly studied glioblastoma in vitro cell line model (26).
This study provided perspective on the instability of the glioblastoma genome and on the scope of functional studies that
must be undertaken to decipher the roles of uncharacterized
genetic aberrations and their protein products in glioblastoma.
Cytoskeletal proteins play a key role in motility, invasion and proliferation (27). In this study we investigated the
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cytoskeletal spectraplakin protein, MACF1, as a potential
diagnostic and prognostic marker and have evaluated its
potential to be a target for glioblastoma therapy. Our findings
that MACF1 was predominantly expressed in glioblastoma
but absent in normal brain tissue and lower grade brain tumors
suggest that MACF1 is a potential tumor-specific marker of
this grade IV brain tumor. Taken together, our finding that
MACF1 downregulation with RNA interference reduces the
proliferation and migration of glioblastoma cells, indicates
that MACF1 expression positively influences the proliferation
and migration of glioblastoma cells. A similar conclusion was
reached in studies by Hu et al (28) and Wu et al (17) which
demonstrated that genetic inhibition and absence of MACF1
causes a cell cycle arrest associated decrease in osteoblastic
cell proliferation and impaired keratinocyte migration, respectively. It should also be mentioned that the role of cell death
was not examined as an underlying cause of the decrease in
glioblastoma cell proliferation and viability in response to
negatively regulating MACF1 function in this study, which is
complicated by the established evasiveness of glioblastomas
from apoptotic cell death in response to various treatment
modalities. In this regard forthcoming studies will examine
whether inhibition of MACF1 promotes apoptotic cell death or
autophagy, the preferred mode of cell death in glioblastomas.
Along with its influence on cell behavior, an early investigation by Chen et al (16) also revealed that MACF1 was involved
in the Wnt-signaling axis and showed that downregulation of
MACF1 decreased nuclear β-catenin and led to an inhibition
of Wnt induced β-catenin-dependent transcriptional activation
in P19 and Rat-1 cells. Paralleling these observations, our
results demonstrate that the scaffolding protein Axin1 and
the transcriptional activator β -catenin of the Wnt signaling
pathway are decreased in cells with suppressed MACF1.
These data indicate that MACF1 contributes to the regulation
of glioblastoma cell proliferation and migration by intervening
in the Wnt-signaling pathway.
Our results also show that although MACF1 is expressed
at similar levels in U251 and A172 glioblastoma cells, its
silencing impedes motility and proliferation in U251, but
not A172 cells. This could be due to heterogeneous genetic
alterations between these two cell lines, such as p53 which
is mutated in U251 and wild-type in A172 or differential
expression of MACF1 isoforms. In support of this hypothesis,
glioblastoma cell lines have been shown to be disparate in their
genetic alterations (29). In addition, several MACF1 isoforms
with different 5'UTRs and variations in the N-terminal
actin-binding domain region have been described (30), but
their functions have yet to be deciphered. Furthermore, it
has been demonstrated that isoform specific silencing of the
actin-binding protein α-actinin in glioblastoma cells has been
shown to lead to different cellular outcomes (31), raising the
possibility that differential expression of MACF1 isoforms
may affect glioblastoma cell behavior. To this end, future
studies will investigate the inhibitory effects of silencing
different MACF1 isoforms that could impair glioblastoma
cell proliferation and migration, particularly in A172 cells that
were impervious to MACF1 inhibition in this study.
Clinically, TMZ is among the lead chemotherapeutic
agents used for the treatment of nervous system cancers,
particularly malignant brain tumors, because of its bioavail-
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ability and limited toxicity (32). However, a caveat of its
efficacy has been intrinsic and acquired resistance as a result
in part of activating pro-survival signaling mediators (33-35).
From a therapeutic precision medicine standpoint, our data
show that in glioblastoma cells in which MACF1 downregulation decreases proliferation and motility, reduced MACF1
levels also enhances the anti-proliferative effect of TMZ.
Interestingly, our results also show that TMZ induces the
expression of MACF1 and Axin1, indicating that MACF1-Wnt
signaling, may contribute to TMZ resistance and perpetuate
glioblastoma cell survival. These data are in line with findings that combinatorial targeted therapy approaches with
TMZ is efficient at enhancing the progression-free survival of
patients with genetically diverse glioblastomas (36-38). Taken
together, our results identify MACF1 as a unique target with
the potential to broaden combinatorial treatment paradigms in
glioblastomas with diverse genetic profiles.
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